Arrhythmias/Electrophysiology
Retrospective Cohort Study: Atrial fibrillation after surgery is linked to an increased risk of hospitalization for heart failure.
29 Jun, 2022 | 10:52h | UTCOriginal Study: Post-operative atrial fibrillation and risk of heart failure hospitalization – European Heart Journal
Commentary on Twitter
Excited to have been part of this study with @ParagGoyalMD and our @WeillCornell colleagues
We found post-operative AF is associated with a higher long-term risk of HF hospitalization 👇https://t.co/X9eh2D9V71 @ESC_Journals @WCMCNeurology pic.twitter.com/5HlsGfOq1j
— Hooman Kamel (@hoomankamel) June 29, 2022
Review: Arrhythmias and heart failure in pregnancy.
29 Jun, 2022 | 10:48h | UTC
Indications and utility of cardiac genetic testing in athletes.
28 Jun, 2022 | 11:03h | UTC
M-A: Direct oral anticoagulants vs. warfarin in hemodialysis patients with atrial fibrillation.
28 Jun, 2022 | 10:48h | UTC
RCT: Effect of MRI-guided fibrosis ablation vs. conventional catheter ablation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation.
23 Jun, 2022 | 12:57h | UTCEffect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial – JAMA (free for a limited period)
News Release: Global AFib study finds simple approach is best for ablation procedures – Tulane University
Commentary on Twitter
Randomized clinical trial of patients with persistent #atrialfibrillation found no significant difference in atrial arrhythmia recurrence in the MRI-guided fibrosis ablation group compared with the pulmonary vein isolation only group. https://t.co/mCyNR4rpTH
— JAMA (@JAMA_current) June 21, 2022
Post Hoc Secondary Analysis of RCT: Rivaroxaban monotherapy is associated with better outcomes vs. combination therapy with antiplatelets in patients with atrial fibrillation and stable coronary artery disease.
17 Jun, 2022 | 11:07h | UTCRivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial – JAMA Cardiology (free for a limited period)
Commentaries:
Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease: Does Less Mean More? – JAMA Cardiology (free for a limited period)
Rivaroxaban Monotherapy Linked to Lower Event Risk in Patients with AF, Stable CAD – HCPLive
Commentary on Twitter
In this post-hoc study of the AFIRE RCT, recurrent event analyses showed that rivaroxaban monotherapy was associated with lower risks of total thrombotic and/or bleeding events than rivaroxaban plus antiplatelet therapy in patients with AF and stable CAD. https://t.co/TGwatvlrKR
— JAMA Cardiology (@JAMACardio) June 15, 2022
Inappropriate sinus tachycardia: etiology, pathophysiology, and management.
16 Jun, 2022 | 11:05h | UTC